TY - JOUR
T1 - Apolipoprotein E ε4 Allele is Associated With Plasma Amyloid Beta and Amyloid Beta Transporter Levels
T2 - A Cross-sectional Study in a Rural Area of Xi'an, China
AU - Wei, Shan
AU - Gao, Ling
AU - Jiang, Yu
AU - Shang, Suhang
AU - Chen, Chen
AU - Dang, Liangjun
AU - Zhao, Beiyu
AU - Zhang, Juanli
AU - Wang, Jin
AU - Huo, Kang
AU - Wang, Jingyi
AU - Zhang, Rong
AU - Qu, Qiumin
N1 - Funding Information:
We were thankful for the cooperation of all participants in our study. Conflicts of Interest and Source of Funding: The authors have no conflict of interest to report. This work was supported by NationalNatural Science Foundation of China (no. 81771168) and the Key Research & Development Programs of Shaanxi Province (no. 2018ZDXM-SF-052). Disclosure: No disclosure to declare.
Funding Information:
Conflicts of Interest and Source of Funding: The authors have no conflict of interest to report. This work was supported by National Natural Science Foundation of China (no. 81771168 ) and the Key Research & Development Programs of Shaanxi Province (no. 2018ZDXM-SF-052 ).
Publisher Copyright:
© 2019 American Association for Geriatric Psychiatry
PY - 2020/2
Y1 - 2020/2
N2 - Objective: The effects of the Apolipoprotein E (ApoE) genotype on peripheral amyloid beta (Aβ) and Aβ transporter levels are still unclear. Soluble low-density lipoprotein receptor-related protein-1 (sLRP1) and soluble receptor of advanced glycation end products (sRAGE) are the major transporter for Aβ, which can prevent plasma Aβ from flowing into brain. The aim of this study was to investigate the relationships between the ApoE genotype and plasma Aβ, sLRP1, sRAGE levels. Design: Cross-sectional study. Setting: The committee office of the village. Participants: Residents lived in the village for more than 3 years, aged 40–85 years (n = 1,119, 63.5% women). Measurements: Plasma biomarkers include ApoE genotype, Aβ, sLRP1, sRAGE, fasting blood-glucose, and blood lipids. General information, medical history, living habits, and cognitive status (cognitive impairment or not) were also collected. Results: After controlling for all possible covariates, multiple linear regression analysis showed that the plasma level of Aβ42 was higher and log-transformed sLRP1 was lower in ApoE ε4 carriers than that in noncarriers (βAβ42 = 1.214, 95% confidence interval: 0.105–2.316, pAβ42 = 0.031; βsLRP1 = −0.075, 95% confidence interval: −0.129 to −0.021, psLRP1 = 0.006, respectively). Partial correlation analysis showed that plasma Aβ40 was positively correlated with log-transformed sLRP1 and log-transformed sRAGE (rsLRP1 = 0.116, psLRP1 <0.001; rsRAGE = 0.078, psLRP1 = 0.009, respectively). Plasma Aβ42 was positively correlated with log-transformed sRAGE (r = 0.072, p = 0.017). Conclusion: ApoE ε4 carriers had higher plasma Aβ42 levels and lower sLRP1 levels. These data indicated that the ApoE ε4 allele may also contribute to the pathogenesis of Alzheimer's disease through its effects on peripheral Aβ42 and sLRP1 levels, but it needs to be further elucidated.
AB - Objective: The effects of the Apolipoprotein E (ApoE) genotype on peripheral amyloid beta (Aβ) and Aβ transporter levels are still unclear. Soluble low-density lipoprotein receptor-related protein-1 (sLRP1) and soluble receptor of advanced glycation end products (sRAGE) are the major transporter for Aβ, which can prevent plasma Aβ from flowing into brain. The aim of this study was to investigate the relationships between the ApoE genotype and plasma Aβ, sLRP1, sRAGE levels. Design: Cross-sectional study. Setting: The committee office of the village. Participants: Residents lived in the village for more than 3 years, aged 40–85 years (n = 1,119, 63.5% women). Measurements: Plasma biomarkers include ApoE genotype, Aβ, sLRP1, sRAGE, fasting blood-glucose, and blood lipids. General information, medical history, living habits, and cognitive status (cognitive impairment or not) were also collected. Results: After controlling for all possible covariates, multiple linear regression analysis showed that the plasma level of Aβ42 was higher and log-transformed sLRP1 was lower in ApoE ε4 carriers than that in noncarriers (βAβ42 = 1.214, 95% confidence interval: 0.105–2.316, pAβ42 = 0.031; βsLRP1 = −0.075, 95% confidence interval: −0.129 to −0.021, psLRP1 = 0.006, respectively). Partial correlation analysis showed that plasma Aβ40 was positively correlated with log-transformed sLRP1 and log-transformed sRAGE (rsLRP1 = 0.116, psLRP1 <0.001; rsRAGE = 0.078, psLRP1 = 0.009, respectively). Plasma Aβ42 was positively correlated with log-transformed sRAGE (r = 0.072, p = 0.017). Conclusion: ApoE ε4 carriers had higher plasma Aβ42 levels and lower sLRP1 levels. These data indicated that the ApoE ε4 allele may also contribute to the pathogenesis of Alzheimer's disease through its effects on peripheral Aβ42 and sLRP1 levels, but it needs to be further elucidated.
KW - Alzheimer's disease
KW - Apolipoprotein E genotype
KW - amyloid beta (Aβ)
KW - risk factors
KW - soluble low-density lipoprotein receptor-related protein-1 (sLRP1)
KW - soluble receptor of advanced glycation end products (sRAGE)
UR - http://www.scopus.com/inward/record.url?scp=85069732567&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069732567&partnerID=8YFLogxK
U2 - 10.1016/j.jagp.2019.06.011
DO - 10.1016/j.jagp.2019.06.011
M3 - Article
C2 - 31350163
AN - SCOPUS:85069732567
SN - 1064-7481
VL - 28
SP - 194
EP - 204
JO - American Journal of Geriatric Psychiatry
JF - American Journal of Geriatric Psychiatry
IS - 2
ER -